Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06359860
Status:
RECRUITING
Last Update Posted:
2024-04-11
First Post:
2024-01-03
Brief Title:
A Study of ST-1898 for Unresectable or Metastatic Melanoma
Sponsor:
Beijing Scitech-Mq Pharmaceuticals Limited
Organization:
Beijing Scitech-Mq Pharmaceuticals Limited
Study Overview
Official Title:
A Phase IbII Study to Evaluate the Efficacy and Safety of ST-1898 in Subjects With Unresectable or Metastatic Melanoma
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
ST-1898 is a receptor tyrosine kinase RTK inhibitor for multi-targets especially for VEGFR2 c-MET AXL PDGFRA RET KIT etc This trial is to evaluate its safety tolerability pharmacokinetic and efficacy in subjects with unresectable or metastatic melanoma
In phase Ib the primary objectives are to assess the safety and tolerability and to determine Recommended Phase 2 dose RP2D of ST-1898 tablets in subjects with unresectable or metastatic melanoma Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy
In phase II the primary objective is to assess the anti-tumor activities of ST-1898 tablets in subjects with unresectable or metastatic melanoma The secondary objective is to evaluate the safety of ST-1898 tablets
In phase Ib the primary objectives are to assess the safety and tolerability and to determine Recommended Phase 2 dose RP2D of ST-1898 tablets in subjects with unresectable or metastatic melanoma Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy
In phase II the primary objective is to assess the anti-tumor activities of ST-1898 tablets in subjects with unresectable or metastatic melanoma The secondary objective is to evaluate the safety of ST-1898 tablets
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None